Milan-based biotech incubator Golgi Neurosciences is teaming up with Danish biopharma Breye Therapeutics to develop the P2X7 receptor antagonist programme for the treatment of retinal disorders.
siRNA specialist Alnylam Pharmaceuticals Roche has received US$310m upfront from Swiss Roche AG for the ex-US commercialisation rights of zilebesiran, an new antihypertensive.
T
The EPO has granted a patent to Domain Therapeutics’ Phase I candidate DT-9081 designed to reverse PGE2-mediated immunosuppression used by tumours to bypass the immune system.
Eli Lilly’s Alzheimer’s drug donanemab has speedy removed amyloid plaques in a pivotal Phase III trail halting disease progression for one year in half of patients.
Hosting leading industry experts from across Europe, Connect in Pharma 2023 revealed future trends in pharma and AI, sustainability, and preventative medicine during a two-day meeting in Geneva on 14 & 15 June.
https://european-biotechnology.com/wp-content/uploads/2024/04/_AAA1925.JPG10001500Margarita Milidakis/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngMargarita Milidakis2023-07-17 13:46:382024-04-02 15:34:18Connect in Pharma 2023 revealed latest trends in pharmaceutical manufacturing and drug delivery
Although the EU Commission wants to abolish the internal combustion engine in individual transport through eMobility, biofuels are far from dead, according to a new study.
https://european-biotechnology.com/wp-content/uploads/2024/04/EG427.png417570Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2023-07-13 10:11:502024-07-09 14:55:18EG 427 expands Series A closing to €18m
Conventional meat production contributes to 15% of the global greenhouse gas emissions, high energy consumption and land use change. Belgian Paleo NV produces alternative protein from myoglobins of different species.
Retinopathy: Golgi and Breye join forces
Latest NewsMilan-based biotech incubator Golgi Neurosciences is teaming up with Danish biopharma Breye Therapeutics to develop the P2X7 receptor antagonist programme for the treatment of retinal disorders.
NK cell therapy company NK:IO raises seed money
Latest NewsBritish NK cell therapy specialist NK:IO Ltd has added a £1.2m seed investment led by Cancer Research Horizons, bringing total seed funding to £5.1m.
Alnylam in US$2.8bn biobucks deal with Roche
Latest NewssiRNA specialist Alnylam Pharmaceuticals Roche has received US$310m upfront from Swiss Roche AG for the ex-US commercialisation rights of zilebesiran, an new antihypertensive.
T
Resistance blocker of immune checkpoint inhibitors gets patented
Latest NewsThe EPO has granted a patent to Domain Therapeutics’ Phase I candidate DT-9081 designed to reverse PGE2-mediated immunosuppression used by tumours to bypass the immune system.
Lilly presents impressing results for Alzheimer’s drug donanemab
Latest NewsEli Lilly’s Alzheimer’s drug donanemab has speedy removed amyloid plaques in a pivotal Phase III trail halting disease progression for one year in half of patients.
Connect in Pharma 2023 revealed latest trends in pharmaceutical manufacturing and drug delivery
Sponsored PublicationsHosting leading industry experts from across Europe, Connect in Pharma 2023 revealed future trends in pharma and AI, sustainability, and preventative medicine during a two-day meeting in Geneva on 14 & 15 June.
Biomethane fuel offers negative carbon footprint
Latest NewsAlthough the EU Commission wants to abolish the internal combustion engine in individual transport through eMobility, biofuels are far from dead, according to a new study.
Carbios raises €141m to boost enzymatic PET recycling
Latest NewsIn an oversubscribed capital increase, Carbios SAS has raised €141m, the largest on Euronext growth since 2015.
EG 427 expands Series A closing to €18m
Latest NewsParis-based gene therapy vector specialist EG 427 SAS has closed a Series A financing at €18m raising additional €5m in the final closing.
Tasteful plant protein
BackgroundConventional meat production contributes to 15% of the global greenhouse gas emissions, high energy consumption and land use change. Belgian Paleo NV produces alternative protein from myoglobins of different species.